IntelGenx Technologies Corp.
IGX
Rang in Aktien
#28108
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Aktienkurs
$0.17446996
Zuletzt synchronisiert: 2024-06-11
Marktkapitalisierung
$26.97M
Veränderung (1 Tag)
-0.57%
Veränderung (1 Jahr)
2.63%
Land
CA
Handel IntelGenx Technologies Corp. (IGX)
Kategorie
Healthcare
P/B-Verhältnis für IntelGenx Technologies Corp. (IGX)
P/B-Verhältnis zum October 2026 TTM: -2.42
Laut den neuesten Finanzberichten und dem Aktienkurs von IntelGenx Technologies Corp. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) -2.42. Am Ende des Jahres 2022 lag das P/B-Verhältnis bei -9.50.
P/B-Verlauf für IntelGenx Technologies Corp. von 2003 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | -2.42 | 23.07% |
| 2023 | -1.97 | -79.26% |
| 2022 | -9.50 | -174.53% |
| 2021 | 12.74 | -150.90% |
| 2020 | -25.03 | -116.69% |
| 2019 | 150.02 | 3,643.29% |
| 2018 | 4.01 | -70.64% |
| 2017 | 13.65 | 35.29% |
| 2016 | 10.09 | 69.93% |
| 2015 | 5.94 | -17.37% |
| 2014 | 7.18 | 18.93% |
| 2013 | 6.04 | -59.22% |
| 2012 | 14.81 | 144.88% |
| 2011 | 6.05 | -27.78% |
| 2010 | 8.38 | 18.81% |
| 2009 | 7.05 | -89.74% |
| 2008 | 68.73 | 13.46% |
| 2007 | 60.57 | 98.05% |
| 2006 | 30.59 | -108.75% |
| 2005 | -349.52 | 279.12% |
| 2004 | -92.19 | -68.86% |
| 2003 | -296.02 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | -357.84% |
US
|
|
| 13.2547 | -646.72% |
US
|
|
| 4.208 | -273.57% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -355.01% |
NL
|
